Efficacy and safety of dexamethasone and prednisone for therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis
Clinical and Investigative Medicine · 01.07.2026 · 49 (2) · 43-55
DOI: 10.3138/cim-2025-0188 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical and Investigative Medicine, erschienen am 01.07.2026. Verfasst von Wenqiong Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Dexamethasone, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prednisone. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background
This meta-analysis examined the efficacy and safety of dexamethasone compared with prednisone in the treatment of acute lymphoblastic leukemia (ALL).
Methods
A search was conducted in PubMed, EMBASE, and the Cochrane Library databases for randomized controlled trials (RCTs) or observational studies involving children diagnosed with ALL who received dexamethasone or prednisone as pharmacotherapy. Studies without access to primary data were excluded. RCTs were assessed using the Cochrane Risk of Bias 2.0 tool, while observational studies were evaluated with ROBINS-I.
Results
Fourteen studies involving 12,665 children were analyzed. Dexamethasone significantly improved event-free survival compared to prednisone (OR 1.40 [95% CI 1.26 to 1.56], P < 0.001). However, the pooled results, which showed significant heterogeneity, indicated a potentially higher incidence of toxicity associated with dexamethasone (OR 1.92 [95% CI 1.32 to 2.81]), a finding that warrants cautious interpretation. Qualitative synthesis further clarified that this increased risk was particularly evident for infectious, neuropsychiatric, and musculoskeletal adverse events. No significant differences were found in remission rates, relapse rates, or mortality between the two glucocorticoids. The GRADE assessment indicated high certainty regarding the evidence for event-free survival.
Conclusions
In children with ALL, dexamethasone improves event-free survival compared to prednisone but may have a higher risk of adverse effects. This highlights the need for a careful benefit-risk assessment. Future research should explore hybrid glucocorticoid strategies to maximize survival outcomes while reducing adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China.
- Department of Obstetrics and Gynaecology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Zitieren
APA
Lv, W., Li, D., Li, J., Xie, Y., & Yang, X. (2026). Efficacy and safety of dexamethasone and prednisone for therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis. Clinical and Investigative Medicine, 49(2), 43-55. https://doi.org/10.3138/cim-2025-0188
Vancouver
Lv W, Li D, Li J, Xie Y, Yang X. Efficacy and safety of dexamethasone and prednisone for therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis. Clinical and Investigative Medicine. 2026;49(2):43-55. doi:10.3138/cim-2025-0188
BibTeX
@article{Lv2026,
author = {Lv, Wenqiong and Li, Dongjun and Li, Jianhua and Xie, Yao and Yang, Xue},
title = {Efficacy and safety of dexamethasone and prednisone for therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis},
journal = {Clinical and Investigative Medicine},
year = {2026},
volume = {49},
number = {2},
pages = {43--55},
doi = {10.3138/cim-2025-0188}
}
EUVIMED